CDC Summaries of EGAPP™ Recommendation Statements
ShareCompartir
This website is archived for historical purposes and is no longer being maintained or updated.
Since 2007, the independent, non-federal Evaluation of Genomic Applications in Practice and Prevention (EGAPP™) Working Group has released six recommendations on the validity and utility of specific genetic tests for individuals diagnosed with breast cancer, colorectal cancer, or depression as well as genetic tests for cardiovascular risk and thrombophilia. The EGAPP Working Group developed these recommendation statements based on the available scientific evidence for these genetic tests, which was collected, analyzed, and graded using specific EGAPP™ methods.
CDC’s Office of Public Health Genomics (OPHG) established the in 2004, and the EGAPP™ Working Group in 2005. OPHG provides brief summaries of the EGAPP recommendation statements which can be used by health care providers, public health practitioners, policy makers and the general public. For example, health care professionals can use this information to make evidence-based decisions about using specific genetic tests in clinical settings with their patients. This information can also help individuals understand what the EGAPP recommendations mean for them and where to find more information.
|
Disease/ |
Genetic Test/Purpose | Test Use | EGAPP™ Recommendation |
|---|---|---|---|
| Breast Cancer: | Tumor gene expression profiling to predict risk of breast cancer recurrence | Prognostic: association of genetic markers with disease severity, progression |
Insufficient evidence to recommend for or against use Read the EGAPP recommendation (January 2009) |
| Cardiovascular Disease: | Cardiogenomic profiling to determine risk of developing heart attack or stroke | Prognostic: association of genetic markers with disease risk | Insufficient evidence to recommend for or against use
Read the EGAPP recommendation |
| Genetic testing for Factor V Leiden and prothrombin variants for idiopathic venous thromboembolism (VTE) | Diagnostic: association of a genetic marker with a disease/condition in a person with symptoms and family members without symptoms |
Sufficient evidence to recommend against routine use in adults with idiopathic VTE; and in their adult family members with no history or symptoms of thrombotic events, for medical decision making on preventive use of anticoagulants Read the EGAPP recommendation |
|
| Colorectal Cancer: | Genetic testing for Lynch syndrome | Diagnostic: association of a genetic marker with a disease/condition in a person with symptoms |
Sufficient evidence to recommend use for the benefit of relatives Read the EGAPP recommendation (January 2009) |
| UGT1A1 genotyping to predict response to Irinotecan chemotherapy | Pharmacogenomic: predicting response to drug treatment |
Insufficient evidence to recommend for or against use Read the EGAPP recommendation (January 2009) |
|
| Depression: | CYP450 genotyping to predict response to Selective Serotonin Reuptake Inhibitors (SSRIs) | Pharmacogenomic: predicting response to drug treatment |
Insufficient evidence to recommend for or against use, but use discouraged pending further research Read the EGAPP recommendation (December 2007) |
- Page last reviewed: July 14, 2015 (archived document)
- Content source: